Phaseline

Targets › TPOR

TPOR (Thrombopoietin receptor): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 3 Phase 2; Hematology, Other; next expected readout Dec 2026.

Receptor for thrombopoietin that regulates hematopoietic stem cell renewal, megakaryocyte differentiation, and platelet formation. Upon activation by THPO, induces rapid tyrosine phosphorylation and activation of JAK2, providing docking sites for many signaling proteins such as STAT5, SHIP/INPP5D, GRB2, SOS1 and PI3K. In turn, These signaling cascades lead to the proliferation, survival, and differentiation of…. (UniProt, P40238)

Open in Phaseline: the race on TPOR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Institute of Hematology & Blood Diseases Hospital, Chinaherombopag olamine
thrombopoietin receptor agonist
TPORPhase 2Chemotherapy-induced Thrombocytopenia; HerombopagDec 2026
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityHerombopag Olamine
Thrombopoietin receptor (TPO-R) agonist
TPORPhase 2ThrombocytopeniaSep 2027

Conditions

Chemotherapy-induced Thrombocytopenia (1) Herombopag (1) Thrombocytopenia (1)

Modalities

small molecule (2)

Companies

Institute of Hematology & Blood Diseases Hospital, China (1) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.